Flutamide: an antiandrogen for advanced prostate cancer

BR Goldspiel, DR Kohler - Dicp, 1990 - journals.sagepub.com
Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or
binding of dihydrotestosterone to the target cell receptor, thus interfering with androgen …

Flutamide: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy; in advanced prostatic cancer

RN Brogden, SP Clissold - Drugs, 1989 - Springer
Synopsis Flutamide is a non-steroidal antiandrogenic drug devoid of hormonal agonist
activity. Flutamide appears to be a specific antiandrogen only at androgen-dependent …

Flutamide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer

RN Brogden, P Chrisp - Drugs & aging, 1991 - Springer
Synopsis Flutamide, a nonsteroidal antiandrogenic drug devoid of hormonal agonist activity,
is used in the treatment of advanced prostate cancer. In previously untreated patients …

Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients

W Oosterlinck, J Casselman, J Mattelaer… - European …, 1996 - karger.com
Objective: In a multicenter study, 905 patients with newly diagnosed advanced prostate
cancer treated with flutamide were followed for safety and side effects. Methods: Flutamide …

The use of flutamide in hormone‐refractory metastatic prostate cancer

DG McLeod, RC Benson Jr, MA Eisenberger… - Cancer, 1993 - Wiley Online Library
In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible
patients with newly diagnosed disseminated adenocarcinoma of the prostate were …

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of “hormone-refractory” prostate cancer

O Sartor, M Cooper, M Weinberger… - JNCI: Journal of the …, 1994 - academic.oup.com
Backgroound The best treatment for patients with “hormone-refractory” metastatic prostate
cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed …

Flutamide in hormone-resistant prostatic cancer

SD Fosså, G Hosbach, E Paus - The Journal of urology, 1990 - Elsevier
Abstract Flutamide (250 mg. orally 3 times daily) yielded a subjective response in 5 of 25
fully evaluable patients with hormone-resistant prostatic cancer. Four additional patients had …

Flutamide monotherapy as primary treatment in advanced prostatic carcinoma.

KP Delaere, EL Van Thillo - Seminars in oncology, 1991 - europepmc.org
Little is known about the efficacy of flutamide monotherapy in previously untreated patients
with prostatic carcinoma. In this study, 40 patients with advanced disease were treated with …

The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment

M Schulz, A Schmoldt, F Donn, H Becker - European journal of clinical …, 1988 - Springer
Flutamide is a nonsteroidal antiandrogen used in the treatment of prostatic carcinoma. We
have investigated the disposition of flutamide and its two major metabolites in ten urological …

Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma

L Boccon-Gibod, G Fournier, P Bottet, JM Marechal… - European …, 1997 - karger.com
Purpose: To compare in a randomized clinical trial the therapeutic efficacy of the
nonsteroidal antiandrogen flutamide 250 mg tid to testicular androgen suppression by …